Exane Derivatives’s International Paper IP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
$387K Buy
9,260
+7,536
+437% +$350K 0.22% 111
2022
Q1
$79.6K Buy
1,724
+1,701
+7,396% +$78.3K 0.02% 499
2021
Q4
$1.08K Sell
23
-1
-4% -$49 ﹤0.01% 702
2021
Q3
$1.29K Sell
24
-8,881
-100% -$494K ﹤0.01% 833
2021
Q2
$518K Buy
8,905
+8,658
+3,505% +$494K 0.12% 174
2021
Q1
$12.7K Buy
247
+163
+194% +$7.93K ﹤0.01% 590
2020
Q4
$3.98K Sell
84
-92
-52% -$4.11K ﹤0.01% 574
2020
Q3
$6.77K Hold
176
﹤0.01% 486
2020
Q2
$5.88K Sell
176
-61
-26% -$1.94K ﹤0.01% 441
2020
Q1
$6.97K Sell
237
-82,835
-100% -$3.07M ﹤0.01% 437
2019
Q4
$3.5M Buy
83,072
+82,937
+61,435% +$3.48M 0.65% 50
2019
Q3
$5.35K Sell
135
-80,302
-100% -$3.14M ﹤0.01% 450
2019
Q2
$3.3M Sell
80,437
-5,079
-6% -$215K 0.58% 55
2019
Q1
$3.75M Buy
85,516
+1,290
+2% +$55.9K 0.74% 42
2018
Q4
$3.22M Buy
+84,226
New +$3.54M 0.58% 48

Other funds holding IP

Exane Derivatives's IP Position: Q2 2022 in Review

Exane Derivatives increased its International Paper (IP) stake by 437% in Q2 2022, buying an estimated $350K and bringing the position to 9,260 shares worth $387K. The position accounts for 0.22% of the portfolio, ranked #111.

Exane Derivatives first reported a position in IP in Q4 2018 and has held it in 15 quarters since. The position peaked at $3.75M in Q1 2019. 862 funds tracked by Wall St. Rank hold IP as of Q2 2022.

  • Exane Derivatives held 9,260 shares of International Paper worth $387K as of Q2 2022.
  • Exane Derivatives bought 7,536 International Paper shares in Q2 2022, an estimated $350K.
  • International Paper made up 0.22% of Exane Derivatives's portfolio in Q2 2022, its #111 holding.
  • Exane Derivatives first reported a position in International Paper in Q4 2018 and has held it in 15 quarters since.
  • Exane Derivatives's International Paper position peaked at $3.75M in Q1 2019.
  • 862 funds tracked by Wall St. Rank held International Paper as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.